<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480594</url>
  </required_header>
  <id_info>
    <org_study_id>082017-019</org_study_id>
    <nct_id>NCT03480594</nct_id>
  </id_info>
  <brief_title>Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway</brief_title>
  <acronym>HPFFF</acronym>
  <official_title>Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway (HP FFF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to evaluate sensitivity and specificity of HP 13C-pyruvate as an
      imaging agent for detection of altered PDH flux in fatty liver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to determine whether nutritional state and fatty liver influence the
      production of [13C]bicarbonate from [1-13C]pyruvate via flux through the pyruvate
      dehydrogenase (PDH) reaction in healthy subjects compared to those with fatty liver. The
      long-term purpose of this work is to develop hyperpolarized 13C imaging as a method to
      directly assess metabolic pathways in the human liver. Many high-impact diseases such as
      insulin resistant states, fatty liver and inborn errors of metabolism are known to alter
      biochemical fluxes and for this reason it is important to detect altered activity in specific
      pathways.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non-randomized prospective, non-blinded, single center, translational research</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bicarbonate:lactate ratio</measure>
    <time_frame>One visit of 6 hours; two injections of HP pyruvate with MRI over 3 hours</time_frame>
    <description>1. The ratio of hyperpolarized [13C]bicarbonate relative to hyperpolarized [1-13C]lactate. This measurement will be monitored from the subject's liver over a ~4 minute period in the MRI system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Labeled glycerol fraction</measure>
    <time_frame>One visit of 6 hours; ingestion of Oral Glycerol with blood draws over 3 hours</time_frame>
    <description>2. The fraction of [U-13C]glycerol that has passed through mitochondrial pathways prior to gluconeogenesis and the fraction of glucose, derived from [U-13C]glycerol, that has passed through the pentose phosphate pathway. This information will be acquired from 13C NMR spectroscopy of glucose and triglycerides from a venous blood sample, obtained after the hyperpolarization exam.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Fatty Liver Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized [13C] Pyruvate Injection</intervention_name>
    <description>HP Pyruvate Injection two times during MRI with 45 minute rest period between in Fatty Liver Patients and Healthy Control Subjects</description>
    <arm_group_label>Fatty Liver Patients</arm_group_label>
    <arm_group_label>Healthy Control Subjects</arm_group_label>
    <other_name>HP Pyruvate Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 to 99 years.

          -  All races, ethnicities and gender identification may be included. Subjects must meet
             all of the inclusion and exclusion criteria to be included in the study.

          -  Either fatty liver diagnosis (defined as &gt;5.6% fat content in the liver) or healthy
             control

          -  While all races and ethnicities will be included, subjects must be able to read and
             speak the English language. Once the protocol is established, Spanish-speaking
             participants will be included.

          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry, for the duration of
             study participation. Should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately.

        Exclusion Criteria:

        Fatty Liver Subjects

          -  No subjects taking hypoglycemic agents or insulin will be enrolled. There is no
             exclusion based on fasting glucose.

          -  Subjects with major mental health conditions such as schizophrenia and bipolar
             disorder that would limit compliance with study requirements will not participate. In
             general, subjects with any form of medical instability such as seizure disorders,
             significant COPD, significant asthma, left ventricular dysfunction will not
             participate.

          -  Medications for control of hypercholesterolemia, hypertriglyceridemia or
             hyperglycemia.

        Healthy Control Subjects

          -  Liver disease or other chronic illness

          -  Diagnosis of type I or type II diabetes

          -  No subjects taking hypoglycemic agents or insulin will be enrolled. There is no
             exclusion based on fasting glucose.

          -  A potential subject with any major medical, surgical or psychiatric condition will not
             participate. These conditions include but are not limited to thyroid disease, chronic
             metabolic illness, known vascular disease, current cancer diagnosis and/or treatment.

          -  Subjects with major mental health conditions such as schizophrenia and bipolar
             disorder that would limit compliance with study requirements will not participate. In
             general, subjects with any form of medical instability such as seizure disorders,
             significant COPD, significant asthma, left ventricular dysfunction will not
             participate.

          -  Medications for control of hypercholesterolemia, hypertriglyceridemia or
             hyperglycemia.

        All Subjects

          -  No prior hepato-biliary surgery.

          -  Donated blood within the prior 4 weeks.

          -  Consume more than 10 grams of ethanol per day.

          -  Cirrhosis or any form of viral hepatitis.

          -  Prior documented hepatic reaction to drugs with a known hepatotoxicity profile such as
             isoniazid, methotrexate, phenytoin, propylthiouracil, valproate, etc.

          -  Pregnant/Lactating

          -  Receiving any other investigational agents.

          -  Any contraindication noted on the UTSWMC MRI Screening Form including implants
             contraindicated at 3T, pacemakers, Implantable Cardioverter Defibrillators (ICD),
             etc., and significant claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeannie D Baxter, RN</last_name>
    <phone>214-645-2726</phone>
    <email>jeannie.baxter@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucy H Christie, BSN, RN</last_name>
    <phone>214-645-2215</phone>
    <email>lucy.christie@utsouthwestern.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of &gt; 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63. Epub 2003 Aug 20.</citation>
    <PMID>12930897</PMID>
  </reference>
  <reference>
    <citation>Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med. 2013 Aug 14;5(198):198ra108. doi: 10.1126/scitranslmed.3006070.</citation>
    <PMID>23946197</PMID>
  </reference>
  <reference>
    <citation>Cunningham CH, Lau JY, Chen AP, Geraghty BJ, Perks WJ, Roifman I, Wright GA, Connelly KA. Hyperpolarized 13C Metabolic MRI of the Human Heart: Initial Experience. Circ Res. 2016 Nov 11;119(11):1177-1182. doi: 10.1161/CIRCRESAHA.116.309769. Epub 2016 Sep 15.</citation>
    <PMID>27635086</PMID>
  </reference>
  <reference>
    <citation>Neeland IJ, Hughes C, Ayers CR, Malloy CR, Jin ES. Effects of visceral adiposity on glycerol pathways in gluconeogenesis. Metabolism. 2017 Feb;67:80-89. doi: 10.1016/j.metabol.2016.11.008. Epub 2016 Nov 27.</citation>
    <PMID>28081781</PMID>
  </reference>
  <reference>
    <citation>Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 May;37(5):1202-19. Review. Erratum in: Hepatology. 2003 Aug;38(2):536.</citation>
    <PMID>12717402</PMID>
  </reference>
  <reference>
    <citation>Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston KA, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, Burgess SC. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest. 2015 Dec;125(12):4447-62. doi: 10.1172/JCI82204. Epub 2015 Nov 16. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1605. Livingston, Kenneth [corrected to Livingston, Kenneth A].</citation>
    <PMID>26571396</PMID>
  </reference>
  <reference>
    <citation>Satapati S, Sunny NE, Kucejova B, Fu X, He TT, Méndez-Lucas A, Shelton JM, Perales JC, Browning JD, Burgess SC. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res. 2012 Jun;53(6):1080-92. doi: 10.1194/jlr.M023382. Epub 2012 Apr 9.</citation>
    <PMID>22493093</PMID>
  </reference>
  <reference>
    <citation>Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011 Dec 7;14(6):804-10. doi: 10.1016/j.cmet.2011.11.004.</citation>
    <PMID>22152305</PMID>
  </reference>
  <reference>
    <citation>Jones JG. Hepatic glucose and lipid metabolism. Diabetologia. 2016 Jun;59(6):1098-103. doi: 10.1007/s00125-016-3940-5. Epub 2016 Apr 5. Review.</citation>
    <PMID>27048250</PMID>
  </reference>
  <reference>
    <citation>Jin ES, Moreno KX, Wang JX, Fidelino L, Merritt ME, Sherry AD, Malloy CR. Metabolism of hyperpolarized [1-(13)C]pyruvate through alternate pathways in rat liver. NMR Biomed. 2016 Apr;29(4):466-74. doi: 10.1002/nbm.3479. Epub 2016 Feb 2.</citation>
    <PMID>26836042</PMID>
  </reference>
  <reference>
    <citation>Jin ES, Sherry AD, Malloy CR. An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver. J Biol Chem. 2016 Sep 2;291(36):19031-41. doi: 10.1074/jbc.M116.742262. Epub 2016 Jul 18.</citation>
    <PMID>27432878</PMID>
  </reference>
  <reference>
    <citation>Jin ES, Sherry AD, Malloy CR. Interaction between the pentose phosphate pathway and gluconeogenesis from glycerol in the liver. J Biol Chem. 2014 Nov 21;289(47):32593-603. doi: 10.1074/jbc.M114.577692. Epub 2014 Oct 6.</citation>
    <PMID>25288790</PMID>
  </reference>
  <reference>
    <citation>Lee P, Leong W, Tan T, Lim M, Han W, Radda GK. In vivo hyperpolarized carbon-13 magnetic resonance spectroscopy reveals increased pyruvate carboxylase flux in an insulin-resistant mouse model. Hepatology. 2013 Feb;57(2):515-24. doi: 10.1002/hep.26028. Epub 2013 Jan 10.</citation>
    <PMID>22911492</PMID>
  </reference>
  <reference>
    <citation>Moreno KX, Moore CL, Burgess SC, Sherry AD, Malloy CR, Merritt ME. Production of hyperpolarized (13)CO(2) from [1-(13)C]pyruvate in perfused liver does reflect total anaplerosis but is not a reliable biomarker of glucose production. Metabolomics. 2015 Oct;11(5):1144-1156. Epub 2015 Jan 9.</citation>
    <PMID>26543443</PMID>
  </reference>
  <reference>
    <citation>Merritt ME, Harrison C, Sherry AD, Malloy CR, Burgess SC. Flux through hepatic pyruvate carboxylase and phosphoenolpyruvate carboxykinase detected by hyperpolarized 13C magnetic resonance. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19084-9. doi: 10.1073/pnas.1111247108. Epub 2011 Nov 7.</citation>
    <PMID>22065779</PMID>
  </reference>
  <reference>
    <citation>Moreno KX, Satapati S, DeBerardinis RJ, Burgess SC, Malloy CR, Merritt ME. Real-time detection of hepatic gluconeogenic and glycogenolytic states using hyperpolarized [2-13C]dihydroxyacetone. J Biol Chem. 2014 Dec 26;289(52):35859-67. doi: 10.1074/jbc.M114.613265. Epub 2014 Oct 28.</citation>
    <PMID>25352600</PMID>
  </reference>
  <reference>
    <citation>Moreno KX, Harrison CE, Merritt ME, Kovacs Z, Malloy CR, Sherry AD. Hyperpolarized δ-[1-(13) C]gluconolactone as a probe of the pentose phosphate pathway. NMR Biomed. 2017 Jun;30(6). doi: 10.1002/nbm.3713. Epub 2017 Mar 8.</citation>
    <PMID>28272754</PMID>
  </reference>
  <reference>
    <citation>Jin ES, Szuszkiewicz-Garcia M, Browning JD, Baxter JD, Abate N, Malloy CR. Influence of liver triglycerides on suppression of glucose production by insulin in men. J Clin Endocrinol Metab. 2015 Jan;100(1):235-43. doi: 10.1210/jc.2014-2404.</citation>
    <PMID>25250633</PMID>
  </reference>
  <reference>
    <citation>Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loudat L, Wodzak M, Klimko C, McMillan E, Butt Y, Ni M, Oliver D, Torrealba J, Malloy CR, Kernstine K, Lenkinski RE, DeBerardinis RJ. Metabolic Heterogeneity in Human Lung Tumors. Cell. 2016 Feb 11;164(4):681-94. doi: 10.1016/j.cell.2015.12.034. Epub 2016 Feb 4.</citation>
    <PMID>26853473</PMID>
  </reference>
  <reference>
    <citation>Pichumani K, Mashimo T, Vemireddy V, Kovacs Z, Ratnakar J, Mickey B, Malloy CR, DeBerardinis RJ, Bachoo RM, Maher EA. Hepatic gluconeogenesis influences (13)C enrichment in lactate in human brain tumors during metabolism of [1,2-(13)C]acetate. Neurochem Int. 2016 Jul;97:133-6. doi: 10.1016/j.neuint.2016.03.015. Epub 2016 Mar 26.</citation>
    <PMID>27020407</PMID>
  </reference>
  <reference>
    <citation>Cheshkov S, Dimitrov IE, Jakkamsetti V, Good L, Kelly D, Rajasekaran K, DeBerardinis RJ, Pascual JM, Sherry AD, Malloy CR. Oxidation of [U-(13) C]glucose in the human brain at 7T under steady state conditions. Magn Reson Med. 2017 Dec;78(6):2065-2071. doi: 10.1002/mrm.26603. Epub 2017 Jan 23.</citation>
    <PMID>28112825</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Craig Riggs Malloy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

